Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2017-11-14
|
| gptkbp:ATCCode |
gptkb:R03DX10
|
| gptkbp:brand |
gptkb:Fasenra
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:form |
autoinjector
pre-filled syringe |
| gptkbp:genericName |
gptkb:benralizumab
|
| gptkbp:halfLife |
15-20 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fasenra
|
| gptkbp:indication |
severe eosinophilic asthma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:mechanismOfAction |
IL-5 receptor alpha-directed cytolytic monoclonal antibody
|
| gptkbp:monoclonalAntibodyType |
gptkb:IgG1_kappa
|
| gptkbp:pregnancyCategory |
not assigned (consult physician)
|
| gptkbp:prescriptionRequired |
https://www.fasenra.com/
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
fever
headache injection site reaction hypersensitivity pharyngitis |
| gptkbp:target |
gptkb:interleukin-5_receptor_alpha
|
| gptkbp:bfsParent |
gptkb:AstraZeneca
|
| gptkbp:bfsLayer |
5
|